News

As Seen In
The Province: UBC achilles research could be key to revolutionary treatment
University studying the injection of cultivated cells from one’s own body to speed the healing...
Press Release,Events
RepliCel Life Sciences Selected to Present at Cavendish Global Health Impact Forum
Unique forum brings together leading family offices and foundations seeking impactful investment and philanthropic opportunities...
As Seen In
Stockhouse: Tech Roundup – RepliCel (V.RP) grows, SoMedia (V.VID) profits, WiLAN (WILN) flounders
By: Gaalen Engen First here’s a little biotech. RepliCel Life Sciences (TSX: V.RP, Stock Forum)...
Press Release
RepliCel Announces 2014 Fourth Quarter and Year-End Financial Results
VANCOUVER, BC – April 29, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP),...
As Seen In
Japan’s Take on Regenerative Medicine: Early Commercialization, Early Reimbursement
By Gail Dutton, Contributing Editor Follow Me On Twitter @GailLdutton New regulations accelerating the approval...
As Seen In
How to Grow a Regenerative Medicine Industry in Canada: Michael May of CCRM
Source: George S. Mack of The Life Sciences Report (4/23/15)There’s a new kind of incubator...
As Seen In
Cell Therapy is “Hair Raising” in a Good Way
RepliCel Targets Low-Risk, Near-Term Opportunities in Regenerative MedicineBy: Gail DuttonThe regenerative medicine company RepliCel Life...
Press Release
RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis
The University of British Columbia Clinical Research Ethics Board Clears Clinical Trial to Proceed with...
Press Release
RepliCel Life Sciences Receives TSX Venture Exchange Approval to Extend Warrant Expiry Dates
VANCOUVER, BC – April 7, 2015 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)...
Press Release
RepliCel Life Sciences Applies to Extend Warrant Expiry Dates
VANCOUVER, BC – April 2, 2015 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)...
Press Release
RepliCel Meets with Japanese Pharmaceutical and Medical Devices Agency (PMDA)
As part of its Japanese partnering strategy, RepliCel seeks advice of Japanese regulators around its...
As Seen In
The Life Sciences Report: Will Stem Cell Profits Measure Up?
To read the article on The Life Sciences Report, click here: It makes no sense...
As Seen In
Stockhouse: RepliCel Hits Lucrative Bio-med Trifecta with Innovative Tech
To read the article on Stockhouse click here Until 2011, RepliCel Life Sciences (TSX: V.RP,...
As Seen In
The Province: Four Biotech Companies that are Helping B.C. Lead the Battle Against Aging
To read the full article on The Province newspaper website click here\n\nA Vancouver-based anti-aging company...
Press Release
RepliCel Life Sciences in Japan for Key Industry Meetings
Autologous cell therapy, RCS-01, to be investigated as a potential treatment for aged, UV-damaged skin...
As Seen In
Financial Post: Seeking to Cure the Incurable
To read the article on the Financial Post website click here.\n\nCanada and Japan are taking...
As Seen In
Streetwise Report Interviews BioWatch News Founder Alan Leong
To read the full report, click here. Biotechnology can be daunting to comprehend, but understanding...
Press Release
RepliCel Submits Clinical Trial Application for its Dermatological Clinical Trial
Autologous cell therapy, RCS-01, to be investigated as a potential treatment for aged, UV-damaged skin...
As Seen In
The Total Tutor Interviews CEO David Hall on BlogTalkRadio
RepliCel’s CEO David Hall is interviewed by The Total Tutor Neil Haley on blogtalkradio. Hall...
As Seen In
Houston Style Magazine Interviews RepliCel CEO
 New Treatment for NFL Players and Pro Athletes Offers New HopeStory by: Jo-CarolynNew York, NY,...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.